Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma.

Tian S, Sudmeier LJ, Zhang C, Madden NA, Buchwald ZS, Shu HG, Curran WJ, Eaton BR, Esiashvili N.

Pediatr Blood Cancer. 2019 Oct 1:e28027. doi: 10.1002/pbc.28027. [Epub ahead of print]

PMID:
31571408
2.

Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?

Fukunaga-Johnson N, Lee JH, Sandler HM, Robertson P, McNeil E, Goldwein JW.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):143-6.

PMID:
9747831
3.

Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma.

Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Sharpe MB, Laughlin S, Bartels U, Scantlebury N, Law N, Malkin D, Skocic J, Richard L, Mabbott DJ.

J Neurosurg Pediatr. 2016 Jul;18(1):29-40. doi: 10.3171/2016.1.PEDS15580. Epub 2016 Mar 25.

PMID:
27015518
4.

Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.

Polkinghorn WR, Dunkel IJ, Souweidane MM, Khakoo Y, Lyden DC, Gilheeney SW, Becher OJ, Budnick AS, Wolden SL.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e15-20. doi: 10.1016/j.ijrobp.2010.11.081. Epub 2011 Apr 12.

PMID:
21481547
5.
6.

Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.

Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7. Epub 2007 Sep 24.

7.

Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.

Wolden SL, Dunkel IJ, Souweidane MM, Happersett L, Khakoo Y, Schupak K, Lyden D, Leibel SA.

J Clin Oncol. 2003 Aug 15;21(16):3079-83.

PMID:
12915597
8.

Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.

Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, Spiegler BJ, Malkin D, Janzen L, Mabbott D.

J Clin Oncol. 2014 Jun 10;32(17):1760-8. doi: 10.1200/JCO.2013.52.3290. Epub 2014 Feb 10.

PMID:
24516024
9.
10.

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.

Saran FH, Driever PH, Thilmann C, Mose S, Wilson P, Sharpe G, Adamietz IA, Böttcher HD.

Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):959-67. Review.

PMID:
9869216
11.

Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival.

Eaton BR, Esiashvili N, Kim S, Weyman EA, Thornton LT, Mazewski C, MacDonald T, Ebb D, MacDonald SM, Tarbell NJ, Yock TI.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):133-138. doi: 10.1016/j.ijrobp.2015.09.014. Epub 2015 Sep 18.

12.

Reducing late effects of radiotherapy in average risk medulloblastoma.

Ibrahim NY, Abdel Aal HH, Abdel Kader MS, Makaar WS, Shaaban AH.

Chin Clin Oncol. 2014 Mar;3(1):4. doi: 10.3978/j.issn.2304-3865.2014.01.03.

13.

Medulloblastoma: time-dose relationship based on a 30-year review.

del Charco JO, Bolek TW, McCollough WM, Maria BL, Kedar A, Braylan RC, Mickle JP, Buatti JM, Mendenhall NP, Marcus RB Jr.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):147-54.

PMID:
9747832
14.

Longterm treatment results of childhood medulloblastoma by craniospinal irradiation in supine position.

Slampa P, Pavelka Z, Dusek L, Hynkova L, Sterba J, Ondrova B, Princ D, Novotny T, Kostakova S.

Neoplasma. 2007;54(1):62-7.

PMID:
17203894
15.

Local control in non-metastatic medulloblastoma.

Christopherson KM, Bradley JA, Rotondo RL, Pincus DW, Fort JA, Morris CG, Mendenhall NP, Marcus RB Jr, Indelicato DJ.

Acta Oncol. 2014 Sep;53(9):1151-7. doi: 10.3109/0284186X.2014.932434. Epub 2014 Jul 3.

PMID:
24991891
16.

Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.

Carrie C, Muracciole X, Gomez F, Habrand JL, Benhassel M, Mege M, Mahé M, Quetin P, Maire JP, Soum F, Baron MH, Clavere P, Chapet S, Gaci Z, Kolodie H, Maingon P, Vie B, Bernier V, Alapetite C, Hoffstetter S, Grill J, Lafay F; French Society of Pediatric Oncology.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):711-6. Epub 2005 May 31.

PMID:
15927408
17.

Preliminary results of conformal radiation therapy for medulloblastoma.

Merchant TE, Happersett L, Finlay JL, Leibel SA.

Neuro Oncol. 1999 Jul;1(3):177-87. doi: 10.1093/neuonc/1.3.177.

18.

Low-dose craniospinal radiation therapy for medulloblastoma.

Halberg FE, Wara WM, Fippin LF, Edwards MS, Levin VA, Davis RL, Prados MB, Wilson CB.

Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):651-4.

PMID:
2004939
19.

Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.

Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, Jones RM, MacDonald SM, Pulsifer MB, Lavally B, Abrams AN, Huang MS, Marcus KJ, Tarbell NJ.

Lancet Oncol. 2016 Mar;17(3):287-98. doi: 10.1016/S1470-2045(15)00167-9. Epub 2016 Jan 30.

PMID:
26830377
20.

Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.

Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs SE.

BMC Cancer. 2010 Aug 23;10:450. doi: 10.1186/1471-2407-10-450.

Supplemental Content

Support Center